Menu
Login

Report Library

All Reports

Hematology-Oncology: An Analysis of Approved Drugs, Pipelines, and Likelihood of Approval

December 01, 2014

This report provides an analysis of approved drugs, pipelines, and FDA approvability for agents for the treatment of blood cancers. This analysis includes:
  • The FDA likelihood of approval (LOA) for hematology-oncology drugs compared to LOAs for cancer drugs as a whole.
  • A breakdown of hematology-oncology drug approvals by year, by indication, and by molecular classification.
  • Popular molecular targets and characteristics of corporate sponsors for pipeline drugs.
For the full report, please download the PDF version at the top of this page. To access other special reports and coverage highlights BioMedTracker has produced for the 2014 ASH meeting, please click on the featured links below.

For our disclosures, please read the BioMedTracker Research Standards.
Disease Group Covered: Oncology
Indications Covered: Castleman's Disease

 Additional Resources: